DGAP-News: Evotec to realign Discovery Chemistry Operations
(firmenpresse) - DGAP-News: Evotec AG / Key word(s): Strategic Company Decision
Evotec to realign Discovery Chemistry Operations
08.07.2013 / 13:29
---------------------------------------------------------------------
Hamburg, Germany - 08 July 2013: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX, ISIN: DE0005664809) today announced that it will close its
Chemistry Operations in Thane, India. All chemistry efforts will now be
performed at its Abingdon (UK) facility, answering to an increasing
requirement to operate closer to the principal R&D laboratories of our
major customers. All project work in Thane will be finished at the end of
September and Evotec (India) Private Ltd will be wound down from then.
As a consequence 120 people will have to leave the company and Evotec will
take a one-time impairment charge of up to
EUR 4 m in Q3 2013. At the same time Evotec confirms its revenue,
profitability and cash guidance for 2013.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: 'Evotec
were due to relocate its Indian chemistry operations in June 2014. During
the due diligence in finding a new facility and because of growing customer
requirements for European-based activities we came to the conclusion to
exit our operations in India completely. Through this realignment we will
be able to most efficiently serve our customers, utilise our UK chemistry
resources and capabilities and also realise some cost savings.
Unfortunately the impact is that we must say goodbye to a first-class work
force in Thane that has so ably supported our customers over the last four
years. I would like to express our sincere gratitude to these employees and
wish them all the best for the future.'
ABOUT THE EVOTEC (INDIA) PRIVATE LIMITED
Evotec (India) Private Limited is a 100% subsidiary of Evotec AG. Its
offering includes custom synthesis, process research and development,
scale-up and analytical services.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic. The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology and inflammation. Evotec has
long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca
and Ono Pharmaceutical. In addition, the Company has existing development
partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim,
MedImmune and Andromeda (Teva) in the field of diabetes, with Janssen
Pharmaceuticals in the field of depression and with Roche in the field of
Alzheimer's disease. For additional information please go to www.evotec.com
FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
Contact Evotec AG:
Dr Werner Lanthaler, Chief Executive Officer, Phone: +49.(0)40.56081-242,
werner.lanthaler(at)evotec.com
End of Corporate News
---------------------------------------------------------------------
08.07.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info(at)evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
220224 08.07.2013
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 08.07.2013 - 13:29 Uhr
Sprache: Deutsch
News-ID 276124
Anzahl Zeichen: 7184
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 281 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Evotec to realign Discovery Chemistry Operations"
steht unter der journalistisch-redaktionellen Verantwortung von
Evotec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
